Integrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.
Alan Kalton
Advertisement
Articles by Alan Kalton
Top industry experts weigh in on what the new year holds for the pharma industry.
Exposing the truth behind AI myths highlighted by COVID.
Advertisement
Latest Updated Articles
Fortifying Defenses Pre-Patent CliffSeptember 8th 2023
Top 5 Most Perpetuated AI Myths, DebunkedMay 6th 2021
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
4
FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
5